189 related articles for article (PubMed ID: 31415381)
1. A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48.
Liang RY; Xu JH; Si CW; Wang S; Shang J; Yu ZJ; Mao Q; Xie Q; Zhao W; Li J; Gao ZL; Wu SM; Tang H; Cheng J; Chen XY; Zhang WH; Wang H; Xu ZN; Wang L; Dai J; Yu YY
Medicine (Baltimore); 2019 Aug; 98(33):e16778. PubMed ID: 31415381
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks.
Chen XF; Fan YN; Si CW; Yu YY; Shang J; Yu ZJ; Mao Q; Xie Q; Zhao W; Li J; Gao ZL; Wu SM; Tang H; Cheng J; Chen XY; Zhang WH; Wang H; Xu ZN; Wang L; Dai J; Xu JH
World J Clin Cases; 2021 Jun; 9(18):4690-4699. PubMed ID: 34222435
[TBL] [Abstract][Full Text] [Related]
3. A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients.
Kim HJ; Kim JH; Yeon JE; Seo YS; Jang JW; Cho YK; Jang BK; Han BH; Lee C; Lee JH; Yoon JH; Kim KM; Kim MY; Kim DY; Park NH; Cho EY; Lee JS; Lee JW; Kim IH; Song BC; Lee BS; Kwon OS
J Korean Med Sci; 2022 Mar; 37(11):e92. PubMed ID: 35315603
[TBL] [Abstract][Full Text] [Related]
4. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B.
Pan CQ; Chan S; Trinh H; Yao A; Bae H; Lou L
World J Gastroenterol; 2015 May; 21(18):5524-31. PubMed ID: 25987775
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
[TBL] [Abstract][Full Text] [Related]
6. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.
Marcellin P; Wong DK; Sievert W; Buggisch P; Petersen J; Flisiak R; Manns M; Kaita K; Krastev Z; Lee SS; Cathcart AL; Crans G; Op den Brouw M; Jump B; Gaggar A; Flaherty J; Buti M
Liver Int; 2019 Oct; 39(10):1868-1875. PubMed ID: 31136052
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
Hou JL; Gao ZL; Xie Q; Zhang JM; Sheng JF; Cheng J; Chen CW; Mao Q; Zhao W; Ren H; Tan DM; Niu JQ; Chen SJ; Pan C; Tang H; Wang H; Mao YM; Jia JD; Ning Q; Xu M; Wu SM; Li J; Zhang XX; Ji Y; Dong J; Li J
J Viral Hepat; 2015 Feb; 22(2):85-93. PubMed ID: 25243325
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results.
Liang X; Gao Z; Xie Q; Zhang J; Sheng J; Cheng J; Chen C; Mao Q; Zhao W; Ren H; Tan D; Niu J; Chen S; Pan C; Tang H; Wang H; Mao Y; Jia J; Ning Q; Xu M; Wu S; Li J; Zhang X; Zhang W; Xiong C; Hou J
Hepatol Int; 2019 May; 13(3):260-269. PubMed ID: 30977033
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Chan HL; Fung S; Seto WK; Chuang WL; Chen CY; Kim HJ; Hui AJ; Janssen HL; Chowdhury A; Tsang TY; Mehta R; Gane E; Flaherty JF; Massetto B; Gaggar A; Kitrinos KM; Lin L; Subramanian GM; McHutchison JG; Lim YS; Acharya SK; Agarwal K;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):185-195. PubMed ID: 28404091
[TBL] [Abstract][Full Text] [Related]
11. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
12. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice.
Kim JH; Jung SW; Byun SS; Shin JW; Park BR; Kim MH; Kim CJ; Park NH
Int J Clin Pharm; 2015 Dec; 37(6):1228-34. PubMed ID: 26364195
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B.
Seo HY; Lee HA; Ko SY; Wang JH; Kim JH; Choe WH; Kwon SY
Clin Mol Hepatol; 2017 Jun; 23(2):154-159. PubMed ID: 28479588
[TBL] [Abstract][Full Text] [Related]
16. Clinical response to long-term tenofovir monotherapy in Korean chronic hepatitis B patients.
Yoo EH; Cho HJ
Clin Chim Acta; 2017 Aug; 471():308-313. PubMed ID: 28687350
[TBL] [Abstract][Full Text] [Related]
17. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
Ling N; Zhou Z; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment.
Agarwal K; Ahn SH; Elkhashab M; Lau AH; Gaggar A; Bulusu A; Tian X; Cathcart AL; Woo J; Subramanian GM; Andreone P; Kim HJ; Chuang WL; Nguyen MH
J Viral Hepat; 2018 Nov; 25(11):1331-1340. PubMed ID: 29851204
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone.
Lin S; Fu Y; Wu W; Chen T; Chen N; Xun Z; Liu C; Ou Q; Zeng Y; Huang H
Int J Med Sci; 2020; 17(10):1458-1463. PubMed ID: 32624702
[No Abstract] [Full Text] [Related]
[Next] [New Search]
